(0.07%) 5 217.50 points
(0.07%) 39 053 points
(0.06%) 18 210 points
(-1.01%) $77.59
(0.36%) $2.22
(-0.18%) $2 320.10
(-0.16%) $27.50
(-0.21%) $986.30
(0.17%) $0.931
(0.34%) $10.94
(0.22%) $0.801
(0.18%) $91.61
4.26% £ 9.80
Live Chart Being Loaded With Signals
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases...
Stats | |
---|---|
Volumen de hoy | 61 886.00 |
Volumen promedio | 396 782 |
Capitalización de mercado | 90.94M |
EPS | £0 ( 2024-01-30 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -9.80 |
ATR14 | £0 (0.00%) |
Scancell Holdings PLC Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Scancell Holdings PLC Finanzas
Annual | 2022 |
Ingresos: | £5.27M |
Beneficio Bruto: | £4.75M (90.04 %) |
EPS: | £-0.0146 |
FY | 2022 |
Ingresos: | £5.27M |
Beneficio Bruto: | £4.75M (90.04 %) |
EPS: | £-0.0146 |
FY | 2022 |
Ingresos: | £0 |
Beneficio Bruto: | £0 (0.00 %) |
EPS: | £-0.00250 |
FY | 2021 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.0392 |
Financial Reports:
No articles found.
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico